Skip to main content
Clinical Trials/NCT02766153
NCT02766153
Terminated
Not Applicable

Exploring the Mechanisms of Resistance of Stem Cells Myeloproliferative Opposite of Tyrosine Kinase Inhibitors in 3d Model Niche Endosteal

Centre Hospitalier Universitaire de Nice1 site in 1 country200 target enrollmentMay 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Myeloproliferative Disorders
Sponsor
Centre Hospitalier Universitaire de Nice
Enrollment
200
Locations
1
Primary Endpoint
Characteristics of cell CD34 + tumor from patients with SMP
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

Myeloproliferative disorders (MPD) include chronic myeloid leukemia (CML) (Ph +) and essential thrombocythemia (ET), the polycythemia vera (PV), myelofibrosis (MF) called SMP Ph. CML is the ultimate model of carcinogenesis. SMP is a characterized by a malignant monoclonal proliferation of a pluripotent hematopoietic progenitor determined by the presence of a balanced translocation between chromosomes 9 and 22 (Ph chromosome) which leads to major changes of a large number of cell functions. Investigators now believe that within the bone marrow exist two types of "hematopoietic niches' niche osteoblastic / endosteal and vascular niche, controlling the maintenance and differentiation of hematopoietic stem cell pool. The endosteal niche, is a hypoxic region near the endosteal trabecular, which provides protection to deeply dormant stem cells. Data from the literature suggest that in the SMP, especially CML, the interaction of malignant stem cells with the microenvironment niche Endosteal could favor their survival and resistance to treatment. The therapeutic management of CML was upset by the use of tyrosine kinase inhibitors (TKIs). However, despite these advances, even in situations of undetectable residual disease, it has been observed relapses of the disease stopped TKI leaving suggest that there is a resistance of leukemic stem cell to TKI.

Work in the group Bipoa "Bio Engineering and Pathophysiology Osteo-Articular" helped develop a 3D model of ex vivo bone formation, which can mimic the endosteal niche. the goal is to apply this model to the SMP of hematopoiesis by referring to normal hematopoiesis. it will be tested the hypothesis that the endosteal ex vivo recess of the 3D modeling allows to highlight a special interaction can promote the persistence of the leukemia stem cell despite the use of effective therapies.

Registry
clinicaltrials.gov
Start Date
May 2016
End Date
December 2020
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with LLC (chronic myeloid leukemia)

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Characteristics of cell CD34 + tumor from patients with SMP

Time Frame: 5 years

Establishment of a stem cell CD34 + tumor bank from patients with SMP

Secondary Outcomes

  • Characteristics of the variation of TKI on CD4+ stem cells(5 years)

Study Sites (1)

Loading locations...

Similar Trials